Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2178)	5/24/2013 7:52:10 PM
From: biomachine56	Read Replies (2) \| Respond to of 2344

BKM120 is the other horse with PX-866. BKM120 appears to be a step behind on the randomized combination studies in mCRC and SCCHN indications. Cowen's Simos once called Roche's PI3K inhibitor GDC-0941 one of the leads. clinicaltrials.gov It looks like it is not moving very quickly or aggressively in clinical development. Safety assessments showed hyperglycemia and in one study ECG issues. The other Roche agent is GDC-0980. This one is also in an equal state. clinicaltrials.gov Common theme is looking at BrCa and/or lung cancer in combo with Herceptin and Avastin. Still in early stage of combo testing. Compare these with Novartis' BKM120. Look at this aggressive program. Due to dosage/formulation work on BEZ235, it looks like BKM120 > BEZ235 on the development preference. clinicaltrials.gov XL147/XL765 are toast. Sanofi/Exelixis pulled the plug on these compounds.